Garibaldi: Perioperative Treatment Patterns in Patients With Stage II-IVa Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC) in the United States (US)
Author(s)
Patel V1, Baglio M2, Cai L3, Gupta P4, Hogan N5, Luo L6, Pyrih N7, Stirnadel-Farrant H1
1Oncology Outcomes Research, AstraZeneca, Cambridge, Cambridgeshire, UK, 2US Medical Affairs, AstraZeneca, Gaithersburg, MD, USA, 3Oncology Biometrics, AstraZeneca, South San Francisco, CA, USA, 4US Medical Affairs, AstraZeneca, New York, NY, USA, 5Global Medical Affairs, AstraZeneca, Cambridge, Cambridgeshire, UK, 6Oncology Medical Above Brand, AstraZeneca, Gaithersburg, MD, USA, 7Oncology Outcomes Research, Global Medical Affairs, Oncology R&D, AstraZeneca Pharmaceuticals LP, Gaithersburg, MD, USA
Presentation Documents
OBJECTIVES: Limited perioperative treatment options exist for patients with resectable GC/GEJC. This study described the current treatment landscape and overall survival (OS) for patients with Stage II-IVa GC/GEJC in the US.
METHODS: Data on adult patients diagnosed with Stage II-IVa GC/GEJC between 01-Jan-2016 and 28‑Feb-2022 were analysed from the Tempus GC/GEJC datasets.
RESULTS: 152 GC and 60 GEJC patients were included. Median (interquartile range) age of patients with GC and GEJC was 62.0 (52.0–71.0) and 68.0 (62.0–73.5) years, with 63.8% and 85.0% male patients, respectively. Most patients had adenocarcinoma (GC:112 [73.7%] and GEJC:54 [90.0%] patients) and ECOG PS ≤1 (GC:95 [62.5%] and GEJC:43 [71.7%] patients). 100 (65.8%) GC and 24 (40.0%) GEJC patients had surgery: 31 (31.0%) and 20 (83.3%) received neoadjuvant treatment, 50 (50.0%) and 7 (29.2%) received adjuvant treatment, 13 (13.0%) and 3 (12.5%) received continuous pre-/post-surgery treatment (not considered neoadjuvant or adjuvant), and 21 (21.0%) and 1 (4.2%) did not receive any perioperative treatment, respectively. Among patients receiving neoadjuvant treatment, 22 (71.0%) and 5 (16.1%) GC patients received FLOT and FOLFOX, respectively, and 16 (80.0%) and 3 (15.0%) GEJC patients received chemoradiotherapy and FLOT, respectively. Among patients receiving adjuvant treatment, 12 (24.0%), 8 (16.0%) and 8 (16.0%) GC patients received FOLFOX, FLOT and chemoradiotherapy, respectively, and 3 (42.9%) and 3 (42.9%) GEJC patients received FOLFOX and immunotherapy, respectively. Median OS (95% CI) from diagnosis for GC and GEJC patients combined who had surgery was 24.1 (20.2–32.5) months, and 15.1 (11.6–27.3) months for patients who did not have surgery.
CONCLUSIONS: Over a third of patients with Stage II-IVa GC or GEJC did not undergo surgery. Among patients who had surgery, >20% of GC patients did not receive perioperative treatment. Irrespective of surgery, median OS was ~2 years or less, indicating an unmet need in GC and GEJC management.
Conference/Value in Health Info
Value in Health, Volume 27, Issue 12, S2 (December 2024)
Code
SA9
Topic
Study Approaches
Topic Subcategory
Electronic Medical & Health Records
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Oncology